This site is intended for U.S. healthcare professionals.
Scalp Hair Response
SALT ≤20 at Week 24
SALT ≤20 at Week 48
At baseline, the overall patient population had more than 50% scalp hair loss, with a mean SALT score of 90.3 for patients on LITFULO 50 mg and 93 for those who received placebo.3
The efficacy and safety of LITFULO were evaluated in a randomized, double-blind, placebo-controlled, phase 2b/3 pivotal study in patients 12 years and older (N=718) with alopecia areata and 50% or more scalp hair loss, including alopecia totalis and alopecia universalis. Patients were randomized to receive LITFULO for 48 weeks or placebo for 24 weeks. At Week 24, all patients received LITFULO and there was no placebo control.1,3
The Severity of Alopecia Tool (SALT) helps visually assess the extent of scalp hair loss.5,6
The SALT score equals the sum of the proportions of scalp hair loss per quadrant5
The SALT score measures hair loss on a scale of 0 (no scalp hair loss) to 100 (complete scalp hair loss). For example, SALT 20 can be defined as 20% scalp hair loss and/or 80% scalp hair coverage1,5
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.